Winter Storm Update: MSK is preparing for the coming storm. Read more

Expanded Access of Lutathera to Treat Midgut Carcinoid Tumors

Full Title

Expanded access protocol for therapeutic use of 177Lu-DOTA0-Tyr3-Octreotate in patients with inoperable, somatostatin receptor positive, neuroendocrine tumors, progressive under somatostatin analogue therapy.


The standard treatment for carcinoid tumors are drugs that are similar to the hormone somatostatin. When the tumor continues to grow, however, there are no other standard therapies.

In this study, researchers are expanding access to an investigational drug for midgut carcinoid tumors called Lutathera. This drug is composed of a somatostatin-like drug attached to a radioactive substance called lutetium-177. When the drug attaches to a somatostatin receptor on the tumor, it releases the radioactive lutetium to kill the cancer cells. Lutathera is given intravenously (by vein).


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have an inoperable or metastatic midgut carcinoid tumor that has continued to grow despite prior treatment with a somatostatin analogue.
  • At least 12 weeks must pass between the completion of prior therapies and entry into the study.
  • This study is for patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact the office of Dr. Lisa Bodei at 212-639-5387.